Loading company
Genmab A/S
GMAB · Nasdaq · ·
Next earnings: November 5, 2026 · before the open
$35.57+0.6%Sep 29 close
- 1M
- +7.0%
- 6M
- +37.7%
- 1Y
- +16.0%
- 5Y
- -17.3%
Genmab A/S is the 73rd largest of 361 graded companies. Showing 5 of them, including GMAB itself. 235 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| vTv Therapeutics Inc.VTVT | D- | — | $36.8M | -12.9% | -$25.3M | — |
| Crinetics Pharmaceuticals, Inc.CRNX | D- | — | $42.2M | -1,189.9% | -$425.2M | — |
| Barinthus Biotherapeutics plcBRNS | D- | — | $0.00 | — | -$26.4M | — |
| Vertex Pharmaceuticals Inc. / MAVRTX | B+ | $133.5B | $12.6B | 35.0% | $3.8B | 30.68 |
| Genmab A/SGMAB | A+ | $2.2B | $3.7B | 25.9% | $1.1B | 2.31 |
356 more biotechnology companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Genmab A/S on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
GMAB · Nasdaq · ·
Next earnings: November 5, 2026 · before the open
$35.57+0.6%Sep 29 close